Management of acute decompensated heart failure: Treatment, controversy, and future directions

Pharmacotherapy

Volumn 26, Issue 8 II, 2006, Pages

  Munger, Mark A ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Acute decompensated heart failure; Diuretic; Inotrope; Natriuretic peptide; Renin angiotensin aldosterone system; Sympathetic nervous system; Vasodilator

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; URODILATIN; VASOACTIVE AGENT; VASODILATOR AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CLINICAL TRIAL; CONFERENCE PAPER; DRUG FATALITY; FOLLOW UP; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE;

ACUTE DISEASE; ATRIAL NATRIURETIC FACTOR; DIURETICS; GUIDELINE ADHERENCE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATOR AGENTS;

EID: 33746700758     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.8part2.131S     Document Type: Conference Paper

References (63)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics: 2006 update. A report from the American Heart Association statistics committee and stroke statistics subcommittee. 2006. Available from http://circ. ahajournals.org/cgi/content/abstract/CIRCULATIONAHA.105.171600vl. Accessed April 14, 2006.
2. Fonarow GC. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med 2001;2(suppl 2):S7-12.
3. Krumholz HM, Chen J, Murillo JE, Cohen DJ, Radford MJ. Admission to hospitals with on-site cardiac catheterization facilities: impact on long-term costs and outcomes. Circulation 1998;98:2010-16.
4. Fonarow GC, for the ADHERE Scientific Advisory Committee. The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(suppl 7):S21-30.
5. Cleland JGF, Swedberg K, Follath F, et al. The EuroHeart failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-63.
6. Zevitz EM. Heart failure. July 7, 2005. Available from http://www.emedicine.com/med/topic3552.htm. Accessed April 7, 2006.
7. Adams KFJ, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J 1998;135(6 pt 2):S204-15.
8. O'Connell JB. The economic burden of heart failure. Clin Cardiol 2000;23(suppl III):III-6-10.
9. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997;18:736-53.
10. Berry C, Murdoch DR, McMurray JJV. Economics of chronic heart failure. Eur J Heart Fail 2001;3:283-91.
11. Centers for Medicare and Medicaid Services. Medicare provider analysis and review file (MEDPAR). National 2001 inpatient discharge database. DRG 127. Baltimore: Centers for Medicare and Medicaid Services, 2001.
12. Adams KF Jr, Fonarow GC, Emerman CL, et al, for the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated failure national registry (ADHERE). Am Heart J 2005;149:209-16.
13. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J 1998;135(6 pt 2):S293-309.
14. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997;30:725-32.
15. Pearson RR, Horne BD, Maycock CAA, et al. An institutional heart failure discharge medication program reduces future cardiovascular readmissions and mortality: an analysis of 19,083 heart failure patients [abstr]. Circulation 2001;104(suppl):II-838.
16. Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 2002;3(suppl 4):S18-27.
17. Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002;10:97-107.
18. Masai T, Sawa Y, Ohtake S, et al. Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg 2002;73:549-55.
19. Stevenson L. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1999;1:251-7.
20. Fonarow GC, Stevenson LW, Steimle AE, et al. Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure [abstr]. Circulation 1994;90(4 pt 2):I-488.
21. Abraham WT, Adams KF, Fonarow GC, et al, for the ADHERE Scientific Advisory Committee and Investigators and the ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (ADHERE). J Am Coll Cardiol 2005;46:57-64.
22. Cuffe MS, Califf RM, Adams KFJ, et al, for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
23. SURVIVE-W Trial Investigators. Comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. Presented at the American Heart Association scientific sessions 2005, Dallas, TX, November 13-16, 2005.
24. O'Connor CM, Gattis WA, Uretsky BF, et al, for the FIRST Investigators. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan international randomized survival trial (FIRST). Am Heart J 1999;138(1 pt 1):78-86.
25. Dies F. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Br J Clin Pract 1986;40(suppl 45):37-9.
26. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6.
27. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105:1348-53.
28. Dormans TPJ, van Meyel JJM, Gerlag PGG, Tan Y, Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996;28:376-82.
29. Stevenson LW, Tillisch JH. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation 1986;74:1303-8.
30. Peacock F, Emerman CL, Costanzo MR, Berkowitz RL, Cheng M, for the ADHERE Scientific Advisory Committee and Investigators. Early initiation of intravenous vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE registry database [abstr]. Ann Emerg Med 2003;42(4 suppl):S26.
31. Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P. Early Ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005;46:2047-51.
32. Katz AM. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 1986;73(3 pt 2):III-184-90.
33. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol 1993;22(4 suppl A):119A-26.
34. Burger AJ, Horton DP, Lejemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-8.
35. Scios Inc. Natrecor (nesiritide) for injection package insert. Fremont, CA; 2005. Available from http://www.sciosinc.com/pdf/natrecorpi_final.pdf. Accessed August 17, 2005.
36. Clarkson PB, Wheeldon NM, Macleod C, Coutie W, MacDonald TM. Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects. Clin Sci (Lond) 1995;88:159-64.
37. Colucci WS, Elkayam U, Horton DP, et al, for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-53.
38. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
39. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001;88:35-9.
40. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000;97:4239-44.
41. Sakata Y, Yamamoto K, Masuyama T, et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 2001;19:1905-12.
42. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91.
43. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5.
44. Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003;9:13-25.
45. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-41.
46. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients ≥65 years of age with heart failure. Am J Cardiol 2000;85:1110-13.
47. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-7.
48. Heywood JT. Temporal characteristics of serum creatinine elevations in patients receiving nesiritide and nitroglycerin [abstr]. Circulation 2005;112(17 suppl II):II-590.
49. McFarlane SI, Winer N, Sowers JR. Role of the natriuretic peptide system in cardiorenal protection. Arch Intern Med 2003;163:2696-704.
50. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004;94:595-601.
51. Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy 2004;24:697-702.
52. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.
53. Abraham WT. Nesiritide does not increase 30-day or 6-month mortality risk [abstr]. Circulation 2005;112(17 suppl II):II-676.
54. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
55. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995;25:794-801.
56. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.
57. + channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-59.
58. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 2004;43:555-61.
59. Follath F, Cleland JG, Just H, et al, for the Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
60. Packer M. REVIVE II: multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure [late-breaking clinical trials II]. Presented at the American Heart Association scientific sessions 2005, Dallas, Texas, November 13-16, 2005.
61. Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res 2001;51:450-62.
62. Mitrovic V, Luss H, Nitsche K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial [online exclusive article]. Am Heart J 2005;150:1239.e1-8.
63. Mitrovic V. SIRIUS II: safety and efficacy of an intravenous placebo controlled randomised infusion of ularitide in a prospective double-blind study in patients with symptomatic, decompensated chronic heart failure. Presented at the European Society of Cardiology congress 2005, Stockholm, Sweden, September 3-7, 2005.